This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Pear Therapeutics | |
|---|---|
| Name | Pear Therapeutics |
| Type | Private |
| Industry | Biotechnology |
| Founded | 2013 |
| Founders | Oren Etzioni; David Liu (scientist); Euan Ashley; Tom Insel |
| Headquarters | Boston, Massachusetts |
| Key people | Galvin Simon; Jens Eckstein |
| Products | ReSET, ReSET-O, Somryst |
Pear Therapeutics is a biotechnology company focused on prescription digital therapeutics and software as medical devices. The company develops evidence-based, regulatory-cleared digital interventions intended to treat disease using cognitive behavioral therapy and digital monitoring. It operates at the intersection of healthcare innovation, digital health policy, and clinical research.
The company was founded in 2013 amid a surge of interest in digital health startups following academic advances at institutions such as Massachusetts Institute of Technology, Harvard University, Stanford University, and Johns Hopkins University. Early leadership included figures with backgrounds at Otsuka Pharmaceutical, Verily, Google, and the National Institute of Mental Health, catalyzing collaborations with academic centers like University of Pennsylvania and Yale University. Pear Therapeutics pursued clinical trials and regulatory strategy aligned with precedents set by firms such as Proteus Digital Health and Propeller Health, navigating reimbursement debates involving Centers for Medicare & Medicaid Services and commercial payers. Strategic milestones included partnerships and pilot programs with health systems including Mass General Brigham, Kaiser Permanente, and Geisinger Health System.
Pear develops prescription digital therapeutics that combine software-delivered interventions with clinician dashboards and remote monitoring similar to platforms from Teladoc Health, Livongo Health, and Omada Health. Flagship products incorporate cognitive behavioral therapy modules derived from research at University of Oxford, University College London, and Columbia University. Notable offerings include programs for substance use disorders, insomnia, and mental health conditions, integrating data streams and interoperability features compatible with Epic Systems, Cerner Corporation, and Allscripts. The company employs techniques in mobile app design, patient engagement, and digital biomarkers paralleling work by Apple Inc., Samsung Electronics, and Fitbit researchers.
Pear pursued clearance pathways with the U.S. Food and Drug Administration leveraging software as a medical device frameworks similar to prior clearances achieved by FDA-cleared companies like Dexcom and Abbott Laboratories. Clinical evidence has been published in peer-reviewed journals compared with standards from trials at National Institutes of Health, Mayo Clinic, and Cleveland Clinic. Randomized controlled trials and real-world evidence studies referenced methodologies used by investigators affiliated with Columbia University Irving Medical Center and University of California, San Francisco. The company engaged in regulatory dialogues reminiscent of interactions between Moderna and regulators during accelerated pathways.
The firm's model combines direct contracting with health systems, value-based arrangements with payers such as UnitedHealth Group and Anthem, Inc., and distribution via specialty pharmacies and clinician prescriptions like models used by Pearson and Philips. Strategic alliances have included collaborations with pharmaceutical companies analogous to partnerships between Novartis and digital therapeutics vendors, as well as technology tie-ups with Amazon Web Services and Microsoft Azure for cloud infrastructure. Commercial initiatives mirrored joint ventures between Roche and digital health firms, enabling co-marketing and data-sharing agreements.
Pear secured venture capital and private financing rounds involving investors from the Silicon Valley and Boston venture ecosystems, similar to funding patterns of startups such as Zocdoc and DraftKings. Backers and strategic investors included healthcare-focused venture funds and corporate venture arms comparable to those of Johnson & Johnson Innovation and Pfizer Ventures. The company navigated revenue recognition and reimbursement challenges that have affected peers like Proteus Digital Health and Livongo Health prior to public offerings or mergers.
Pear faced critique regarding clinical effectiveness, pricing, and reimbursement echoing debates around digital therapeutics peers including Akili Interactive and Click Therapeutics. Critics from academic centers such as Yale School of Medicine and policy analysts at Brookings Institution questioned generalizability of trial populations and long-term outcomes, while payers like Blue Cross Blue Shield Association scrutinized cost-effectiveness. Privacy advocates referenced concerns similar to those raised around data practices at Facebook and Cambridge Analytica, prompting discussions about data governance, informed consent, and security practices akin to controversies involving Epic Systems and cloud providers.
R&D activities have involved randomized trials, implementation science, and interoperability work with electronic health record vendors including Epic Systems Corporation and Cerner, and academic partners like Columbia University, Stanford Medicine, and Massachusetts General Hospital. The company has pursued biomarker development and patient-reported outcome instruments in collaboration with consortia such as Clinical Data Interchange Standards Consortium and academic networks like PCORI-funded initiatives. Ongoing research pipelines explore indications that overlap with pharmaceutical trials led by organizations such as GlaxoSmithKline, Eli Lilly and Company, and Bristol Myers Squibb.
Category:Digital therapeutics companies Category:Biotechnology companies of the United States